Reports Q1 revenue $15.5B, consensus $15.33B. “Our company made strong progress to start the year, with increasing contributions from our newer commercialized medicines and vaccines and continued advancement of our pipeline,” said Robert M. Davis, chairman and chief executive officer, Merck (MRK). “We are working with focus and urgency to both realize the full potential of our near-term opportunities and to rapidly progress the next wave of innovation that will positively impact the lives of patients and drive future value creation for all of our stakeholders.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Notable companies reporting before tomorrow’s open
- CoreWeave initiated, eBay downgraded: Wall Street’s top analyst calls
- Trump looking at cutting drug prices to international levels, Reuters says
- Merck initiated with a Neutral at Cantor Fitzgerald
- MRK Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue